Eli Lilly has issued cease-and-desist letters to several companies selling compounded versions of its diabetes drug Mounjaro and weight loss medication Zepbound, citing deceptive advertising practices.
Tirzepatide , the active ingredient in Eli Lilly ’s diabetes drug Mounjaro and weight-loss medication Zepbound, was on the US Food and Drug Administration’s shortage list from December 2022 until October 2, 2024. When drugs in the US go into shortage, pharmacists, doctors, and licensed outsourcing facilities are permitted to “compound” copies to make sure patients have access to medicine they need.
Some pharmacists say that even people who do want to—and can afford to—switch to the name-brand products may run into trouble getting the medications right away. At a roundtable held on October 9 by the Alliance for Pharmacy Compounding, four pharmacists said they were still having trouble filling name-brand tirzepatide prescriptions.
Tirzepatide Mounjaro Semaglutide Ozempic Wegovy Compounded Drugs FDA Shortage Eli Lilly Legal Action
United States Latest News, United States Headlines
Similar News:You can also read news stories similar to this one that we have collected from other news sources.
Tech roars back, and Eli Lilly sends a welcome signal on its growth prospectsEvery weekday, the Investing Club releases the Homestretch; an actionable afternoon update just in time for the last hour of trading.
Read more »
Why Eli Lilly and Palo Alto Networks are both up on news from their competitorsEvery weekday, the Investing Club releases the Homestretch; an actionable afternoon update just in time for the last hour of trading.
Read more »
Eli Lilly to build $4.5 billion research and manufacturing center to propel drug pipelineLilly has 11 obesity drugs in its pipeline and wants to develop more treatments for Alzheimer’s disease, ALS and other brain diseases, CEO David Ricks…
Read more »
Eli Lilly and Company announce $4.5 billion investment in Lebanon LEAP district facilityOn Wednesday, Eli Lilly and Company announced a $4.5 billion investment into a new 'first of its kind' facility in Lebanon's LEAP district.
Read more »
Eli Lilly investing $4.5 billion more into the LEAP district; residents question IEDC's transparencyMeredith Hackler joined WRTV as a Multi-Media Journalist and Reporter in February of 2022.
Read more »
NRA takes aim at Ohio Senate race with ad targeting Sherrod Brown’s gun recordPolitical News and Conservative Analysis About Congress, the President, and the Federal Government
Read more »